Preclinical development of specific tau-binding compounds to target underlying disease mechanisms for the treatment of dementia

The aim of this project is to utilise a newly established, cutting-edge drug discovery platform to conduct a large (14 billion compounds in total) compound screen to identify candidates that can bind to tau. Newly identified candidates will then be subjected to several in vitro assays to determine their potential use for the treatment of Alzheimer’s disease. This work will lay the foundation for a larger study that will then test the most promising candidates in vivo. The pre-clinical data from these studies will then be used to generate a compound portfolio for clinical translation and commercialisation.